Genialis

A major hurdle in oncology? 🚧 Predicting which patients will respond to treatment. This weekend at #SITC24, we're highlighting how biomarkers like Xerna™ TME Panel can help. ↪️ Its potential as a predictive biomarker was demonstrated in the latest retrospective results from HotSpot Therapeutics, Inc.'s ongoing Phase 1 (SOLAR1) study. ✅ Analyses from a subset of patients suggested that those with 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗼𝗳 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗯𝗲𝗻𝗲𝗳𝗶𝘁 generally had 𝗵𝗶𝗴𝗵 𝗫𝗲𝗿𝗻𝗮 𝗶𝗺𝗺𝘂𝗻𝗲 𝘀𝗰𝗼𝗿𝗲𝘀. See the poster #1310 and meet our team tomorrow in Houston! This builds on our work with 7 cancer drugs of unique mechanisms. In every case, we’ve been able to define responder subgroups. 🤝 Learn more about our latest advancements and how our partnership with India-based 4baseCare is helping ensure our biomarkers benefit populations worldwide: https://lnkd.in/dTUjX_Hp

Digital technologies are transforming medical diagnostics 𝗳𝗮𝘀𝘁𝗲𝗿 𝘁𝗵𝗮𝗻 𝗲𝘃𝗲𝗿. 💨 But bringing AI into this field comes with its own set of challenges and opportunities. At yesterday's #BIOEurope2024, Genialis' CTO, Miha Stajdohar, joined a thought-provoking panel discussion, “Why Did It Have to Be Me?”: AI for Diagnosis, alongside Ralf Huss (BioM Biotech Cluster Development GmbH), David Krummen (Vektor Medical, Inc.), Andrea Gisle Joosen (Zühlke Group), and Andrea Riposati (Dante Labs). If you missed it, catch up with our team at #SITC24 this weekend or at #AIDDD next week!

🧬 Discover the Power of AI in Biopharma – Exclusive session –  “Why Did It Have to Be Me?”: AI for Diagnosis AI is reshaping diagnostics! Discover how enhanced digital technologies are improving accuracy and efficiency in medical diagnostics in this session at #BIOEurope2024. 📅 Date: Tuesday, November 5th ⏰ Time: 16:45 - 17:30 📍Location: Room K1 🧑🏫 Moderator: Bora Erdemli, Partner at ZS Speakers include: Ralf Huss (BioM), David Krummen (Vektor Medical, Inc.), Andrea Gisle Joosen (Zühlke Group), Miha Stajdohar (Genialis) and Andrea Riposati (Dante Labs). #AIDiagnostics #BIOEurope2024 #AIforHealthcare #PrecisionMedicine #VentureCapital

The key to providing patients with the most suitable therapies? Biomarker testing. 💡 That’s the focus of the poster we recently presented at #ENA24. In case you missed it, see it here: https://lnkd.in/d67WPS7S,  or connect with Genialis at upcoming events: 🟡 Miha Stajdohar joining a panel 'AI for Diagnosis' at #BIOEurope | November 5, 16:45 | Stockholm, Sweden 🟡 Poster presentation at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting | November 9 | Houston, TX

From Friday runs to finish lines 💪 After 6 months of training, our team conquered the 5k, 10k, and half marathon in Slovenske Konjice—with a 7kg chocolate boost at the end 🤗

It's true, there are many targeted treatment options for NSCLC, with even more in active clinical development. ❓But how many patients 𝗮𝗰𝘁𝘂𝗮𝗹𝗹𝘆 𝘂𝗻𝗱𝗲𝗿𝗴𝗼 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 to ensure they receive the most effective therapies? In collaboration with University Clinic Golnik, we’re presenting a poster at #ENA24, where we analyzed testing rates and observed frequencies of key molecular alterations 🧬 (EGFR, KRAS, BRAF, ALK, ROS1) and PD-L1 expression in 1,600 patients. (This represents around 40% of all NSCLC cases diagnosed in Slovenia, including early-stage cases that are rarely reported globally.) Our findings? Over 𝟵𝟱% of late-stage patients with identified biomarkers received targeted therapy in early lines of treatment. Biomarker testing, in both early and late-stage NSCLC, is essential to providing patients with the most suitable therapies. 💡 Learn more from our poster (https://lnkd.in/d67WPS7S) or catch it live in Barcelona! ✍ Katja Mohorčič, Roman Luštrik, Žan Kuralt, Mark Uhlik, Izidor Kern, Luka Ausec

⚕️ 💻 What are some of the ways we in the AI for Drug Discovery and Development can contribute to better patient outcomes, especially for under-represented patient groups? 🏥 🌍 That was the over-arching question I tried to address in a recent interview with Authority Magazine. We spoke about acknowledging and filling data gaps, building trust with empathy and the difference between a system for healthcare and sick care, among many other topics. Please have a read and leave a comment below to join the conversation. https://lnkd.in/gz2iwym5 These are important conversations to have, so if you'd like to get more involved in this problem space, please follow Genialis and The Alliance for Artificial Intelligence in Healthcare (AAIH). I would also whole-heartedly recommend the leadership of the Digital Medicine Society (DiMe) and Jennifer Goldsack. H/t to Ricky Mehra for opening my eyes to the health v sick care distinction. Thanks for the soapbox, Authority Magazine Interview-Series !!

“I think it’s fair to say that QIAGEN literally democratized access to molecular biology for thousands of labs all over the world. It started more than 40 years ago. And we need to remember, if we close our eyes, that there is probably a before and after QIAGEN in molecular techniques.” If you hadn't had the chance to listen to the latest episode of Talking Precision Medicine featuring Thierry BERNARD, tune in here: https://lnkd.in/dpG2pwsQ

📸: Miha Stajdohar presenting how the Xerna TME Panel earned the confidence of drug developers and regulators at #XAIB24. This afternoon, catch him in a panel discussion on responsible AI with  Richard Milne (University of Cambridge), Stein Aerts (VIB), and Philip Kim (Fable Therapeutics).

📸: Genialis' Joshua Wheeler, MD, PhD, presenting at the PanCAN Scientific Summit 2024 Meet the rest of our team this fall at: 🟡 Explainable AI in Biology Conference 2024 | October 15-18, 2024 | Cambridge, United Kingdom | The BioDev Network 🟡 HLTH 2024 | October 20-23 | Las Vegas, NV | HLTH USA 🟡 ENA 24 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics | October 23-25, 2024 | Barcelona, Spain | EORTC - European Organisation for Research and Treatment of Cancer, National Cancer Institute (NCI), American Association for Cancer Research 🟡 SITC 39th Annual Meeting & Pre-Conference Programs | November 6-11 | Houston, TX | Society for Immunotherapy of Cancer (SITC) See you there!